These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11470610)

  • 1. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery.
    Chaturvedi PR; Decker CJ; Odinecs A
    Curr Opin Chem Biol; 2001 Aug; 5(4):452-63. PubMed ID: 11470610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADMET in silico modelling: towards prediction paradise?
    van de Waterbeemd H; Gifford E
    Nat Rev Drug Discov; 2003 Mar; 2(3):192-204. PubMed ID: 12612645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for absorption screening in drug discovery and development.
    Bohets H; Annaert P; Mannens G; Van Beijsterveldt L; Anciaux K; Verboven P; Meuldermans W; Lavrijsen K
    Curr Top Med Chem; 2001 Nov; 1(5):367-83. PubMed ID: 11899103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico and Ex silico ADME approaches for drug discovery.
    Darvas F; Keseru G; Papp A; Dormán G; Urge L; Krajcsi P
    Curr Top Med Chem; 2002 Dec; 2(12):1287-304. PubMed ID: 12470281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and metabolism in early drug discovery.
    Smith DA; van de Waterbeemd H
    Curr Opin Chem Biol; 1999 Aug; 3(4):373-8. PubMed ID: 10419843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of in vitro Caco-2 permeability and liver microsomal half-life screens in discovering BMS-488043, a novel HIV-1 attachment inhibitor with improved pharmacokinetic properties.
    Yang Z; Zadjura LM; Marino AM; D'Arienzo CJ; Malinowski J; Gesenberg C; Lin PF; Colonno RJ; Wang T; Kadow JF; Meanwell NA; Hansel SB
    J Pharm Sci; 2010 Apr; 99(4):2135-52. PubMed ID: 19780144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput and in silico techniques in drug metabolism and pharmacokinetics.
    van de Waterbeemd H
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):33-43. PubMed ID: 11865671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.
    Stoner CL; Cleton A; Johnson K; Oh DM; Hallak H; Brodfuehrer J; Surendran N; Han HK
    Int J Pharm; 2004 Jan; 269(1):241-9. PubMed ID: 14698595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back to basics: understanding drugs in children: pharmacokinetic maturation.
    Tetelbaum M; Finkelstein Y; Nava-Ocampo AA; Koren G
    Pediatr Rev; 2005 Sep; 26(9):321-8. PubMed ID: 16140874
    [No Abstract]   [Full Text] [Related]  

  • 13. Computational approaches towards the rational design of drug-like compound libraries.
    Matter H; Baringhaus KH; Naumann T; Klabunde T; Pirard B
    Comb Chem High Throughput Screen; 2001 Sep; 4(6):453-75. PubMed ID: 11562252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When poor solubility becomes an issue: from early stage to proof of concept.
    Stegemann S; Leveiller F; Franchi D; de Jong H; Lindén H
    Eur J Pharm Sci; 2007 Aug; 31(5):249-61. PubMed ID: 17616376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds.
    Tarbit MH; Berman J
    Curr Opin Chem Biol; 1998 Jun; 2(3):411-6. PubMed ID: 9691080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in computationally modeling human oral bioavailability.
    Wang J; Hou T
    Adv Drug Deliv Rev; 2015 Jun; 86():11-6. PubMed ID: 25582307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting pharmacokinetic profiles using in silico derived parameters.
    Hosea NA; Jones HM
    Mol Pharm; 2013 Apr; 10(4):1207-15. PubMed ID: 23427934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in predicting human ADME parameters in silico.
    Ekins S; Waller CL; Swaan PW; Cruciani G; Wrighton SA; Wikel JH
    J Pharmacol Toxicol Methods; 2000; 44(1):251-72. PubMed ID: 11274894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.